Ovagen is a tripeptide, a three-amino-acid chain also called T-35, studied as a kidney bioregulator [8][1]. A bioregulator here is a short peptide proposed to switch tissue-specific gene programs on or off. The sources name no parent protein; the closest natural material is a polypeptide complex isolated from calf kidney, tested alongside the tripeptide [1]. A 2021 systematic review lists the peptide as Ovagen [8].
A 2014 paper by Vladimir Khavinson and colleagues at the I. P. Pavlov Institute of Physiology in St. Petersburg reported that Ovagen regulated signaling molecules in aging kidney cell cultures [1]. A separate 2014 study found that the kidney tripeptides T-31 and T-35, with the pineal tetrapeptide epitalon, limited tubular injury, oxidative stress and energy failure in experimental rhabdomyolysis [3]. Khavinson's laboratory framed these short peptides as organ-specific regulators that act on gene expression [5][8].
The research potential is concentrated in kidney protection: acute injury from gentamicin, cisplatin and ischemia-reperfusion, plus aging-related decline [4][6][7]. As of October 2026, Ovagen has no approved human drug product and no registered clinical trial; the evidence is preclinical, and the sources contain no human safety or pharmacokinetic data. WADA's 2026 list does not name Ovagen; its S0 class covers substances with no current government approval for human therapeutic use that no later section addresses [11]. The NCAA banned list does not name it either, and its peptide-hormone class carries a catch-all for related substances [12]. For a short peptide, identity and purity are practical questions; the guide to reading a COA explains the tests tracked in the COA library.
Key takeaways
- Ovagen is a three-amino-acid peptide, also called T-35 [1], studied as a kidney bioregulator; a 2021 review also lists it for liver protection [8].
- In rat models, Ovagen improved urine output, creatinine handling and sodium balance after cisplatin, gentamicin and ischemia-reperfusion injury, and in old rats [4][6][7].
- No human trial of Ovagen appears in the sources reviewed or on ClinicalTrials.gov, and Ovagen has no approved human drug product; WADA's S0 class covers unapproved substances and the NCAA peptide-hormone class covers related ones [11][12].
How it works
Gene regulation through direct DNA binding
Ovagen may work by binding DNA and changing which genes a kidney cell reads. DNA is the cell's instruction molecule, and transcription is the step that copies a gene into RNA, the working copy used to build a protein. The minor groove is the smaller of the two spiral grooves that run along the DNA double helix, and docking is a computer method that fits a molecule into a three-dimensional structure to estimate how well it binds.
The 2016 docking study built models for 19 short peptides and placed Ovagen at ctcc DNA sites [5]. The same paper placed Bronchogen, a four-amino-acid peptide studied for lung cells, at the same ctcc site [5][8]. The result suggests that short peptides can share a DNA site even when their tissue effects differ, though the paper does not test that idea in cells [5][8].
The 2014 renal culture study reached a different modeling result: Ovagen and Cartalax formed their most favorable complexes with a repeating AT sequence in the minor groove [2]. Both results are models, not measured structures. The 2021 review calls Ovagen a DNA binder, and the two papers agree on the general idea of direct DNA contact while disagreeing on the preferred site [2][5][8].
Cell renewal and the aging kidney
Ovagen may slow some features of kidney cell aging by shifting the balance toward division and away from growth arrest. Cell senescence is a state in which a cell stops dividing and releases inflammatory signals, and it accumulates in the kidney with age. p16, p21 and p53 are proteins that brake the cell cycle, and SIRT-6 is a sirtuin, an enzyme linked to DNA repair and longevity.
In primary kidney cell cultures, Ovagen (T-35) changed the expression of MMP-14, a gelatinase that breaks down and remodels the matrix between cells [1]. The study measured Ki-67 and p53 as cell-renewal markers and reported that the calf kidney polypeptide complex and T-31 activated renewal, while Ovagen's main signal was MMP-14 [1]. IL-8, an inflammatory chemokine, was also measured as an immune-response marker.
In aging renal cell cultures, Cartalax and Ovagen increased proliferation and lowered p16, p21 and p53, while raising SIRT-6 in both young and aged cultures [2]. The effect appeared in cells, not in intact kidney, and the abstract does not report a dose or a percent change.
Transport into kidney cells
Ovagen may reach its target through nutrient transporters on the cell surface. LAT1 and LAT2 are amino acid transporters, proteins that carry neutral amino acids across the cell membrane. PEPT1 is a di- and tripeptide transporter, a protein that carries two- and three-amino-acid peptides into the cell. A transporter is a gate, and a peptide that fits the gate can enter without a dedicated receptor.
The 2023 docking study modeled 26 biologically active ultrashort peptides against LAT1, LAT2, PEPT1 and PEPT2, with 8,400 di- and tripeptides as comparators [10]. Ovagen ranked fourth of 26 at LAT1 and tenth at PEPT1. It ranked 24th at LAT2 and 25th at PEPT2, so the strongest predicted routes were LAT1 and PEPT1.
A 2022 review of POT and LAT carriers proposes that transporter expression helps explain why short peptides act on some tissues and not others [9]. The review covers Ovagen among the peptides, but the transport evidence for it is computational. No experiment in the sources measured how much of the tripeptide enters kidney cells or how quickly it leaves.
Nephroprotection after acute injury
Ovagen may protect kidney tubules during acute kidney injury, a sudden loss of filtering function that can follow infection, drugs or reduced blood flow. The tubules are the long channels that reabsorb water, sodium and glucose after the glomerulus filters blood. Oliguria is low urine output, azotemia is the buildup of urea and creatinine, and proteinuria is protein leaking into urine.
In experimental rhabdomyolysis, muscle breakdown releases myoglobin, a heme protein that injures tubules; the kidney tripeptides T-31 and T-35, with epitalon, limited tubular injury, oxidative stress and energy failure [3]. In cisplatin-induced acute renal failure, Ovagen normalized diuresis, urine creatinine concentration and excretion, glomerular filtration rate and absolute sodium reabsorption, and it reduced urine protein [4].
In gentamicin and ischemia-reperfusion models, Ovagen prevented oliguria and azotemia, lowered proteinuria and sodium excretion, prevented the fall in antioxidant enzyme activity, suppressed lipid peroxidation and normalized energy supply [6]. Lipid peroxidation is oxidative damage to membrane fats, and antioxidant enzymes are the cell's defense against it.
In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen raised diuresis 1.2 to 1.4 times, and Ovagen raised sodium excretion 1.6 times, with no morphological or antioxidant evidence of nephrotoxicity [7].
What has been studied in humans
As of October 2026, no human study of the Ovagen tripeptide has been published, and a ClinicalTrials.gov search on October 23, 2026 returned no registered trial. The record in the sources reviewed is entirely preclinical: primary kidney cell cultures and rats [1][6].
No human pharmacokinetic study shows how much of the tripeptide reaches kidney tissue, and no human safety study reports adverse events. Most of the animal work uses acute injury models, and the abstracts do not report long-term follow-up, so the studies cannot show whether benefit lasts or whether repeated exposure is safe [3][7].
None of the cited studies used human participants. The cell work uses primary kidney cultures, and the abstracts do not always state the species [1][2]. A first-in-human study would need a characterized drug substance, a measured exposure profile and a toxicology package; the sources reviewed contain none of that for Ovagen.
Lab and animal studies
Preclinical means work in cells, tissue or animals before a treatment reaches human testing. The Ovagen literature is small and almost entirely renal. The 2021 and 2022 reviews list hepatoprotection, but none of the primary papers tested liver injury [8][9].
In primary kidney cell cultures, Ovagen (T-35) changed MMP-14, a gelatinase that remodels the matrix between cells, while the polypeptide complex and T-31 activated cell renewal [1]. In aging cultures, Ovagen raised proliferation and lowered p16, p21 and p53, three brakes on the cell cycle, while raising SIRT-6, a sirtuin linked to DNA repair and longevity [2]. The same paper built models of Ovagen in the DNA minor groove at a repeating AT sequence, a proposed route to gene regulation rather than a measured one [2].
Most of the animal work tests acute kidney injury. In rhabdomyolysis, the kidney tripeptides T-31 and T-35, with epitalon, limited tubular injury, oxidative stress and energy failure [3]. In cisplatin nephropathy, Ovagen normalized diuresis, creatinine excretion, glomerular filtration and sodium reabsorption [4]. In gentamicin and ischemia-reperfusion injury, Ovagen prevented oliguria, azotemia and proteinuria and preserved antioxidant enzymes [6].
In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen increased urine output 1.2 to 1.4 times, and Ovagen increased sodium excretion 1.6 times, without morphological or antioxidant evidence of nephrotoxicity [7]. Doses are not in the abstracts, the models are mostly acute, and the studies come from a small group of laboratories. No primate or human tissue study appears in the sources reviewed.
Research in detail
Primary kidney cell culture study during in vitro aging with peptide treatment · Primary kidney cell cultures during in vitro aging
The calf kidney polypeptide complex and T-31 activated cell renewal, while Ovagen (T-35) targeted MMP-14; Ki-67, p53 and IL-8 were also measured.
Evidence scope: Abstract reviewed; full text not read. The abstract does not give peptide concentrations, culture species, group sizes or statistics, and it lists a single institute affiliation.
Aging renal cell culture experiments with peptide treatment and DNA interaction modeling · Young and aged renal cell cultures
Cartalax and Ovagen increased proliferation, lowered p16, p21 and p53, and raised SIRT-6; modeling placed both peptides in the DNA minor groove at a repeating AT sequence.
Evidence scope: Abstract reviewed; full text not read. Cell culture only, with no animal or human tissue, and the DNA interaction is a computational model.
Experimental rhabdomyolysis model of acute kidney injury · Animals with experimental rhabdomyolysis (species not stated in the abstract)
Kidney tripeptides T-31 and T-35, with epitalon, limited tubular cell injury, oxidative stress and energy imbalance, and the authors reported correlations among these mechanisms.
Evidence scope: Abstract reviewed; full text not read. The abstract does not state the species, separate the effect of each peptide, give doses or report group sizes.
Rat model of cisplatin-induced acute renal failure with peptide treatment · Rats with cisplatin-induced acute renal failure
Ovagen normalized diuresis, urine creatinine concentration and excretion, glomerular filtration rate and absolute sodium reabsorption, and reduced urine protein; the authors called it a potent nephroprotective effect.
Evidence scope: Abstract reviewed; full text not read. Single model, no dose or group size in the abstract, and no long-term follow-up.
Computational docking of 19 short peptides to DNA · Spatial models of peptide-DNA complexes, with no cells or animals
Ovagen and Bronchogen docked to ctcc DNA sites; the paper proposes direct DNA binding as a route to gene regulation.
Evidence scope: Abstract reviewed; full text not read. Docking only, with no experimental binding measurement, and the preferred site differs from the repeating AT site reported in the 2014 renal culture paper.
Rat models of gentamicin-induced nephropathy and ischemia-reperfusion kidney injury · Rats with acute kidney injury from gentamicin or ischemia-reperfusion
Ovagen prevented oliguria and retention azotemia, lowered proteinuria and sodium excretion, prevented the fall in antioxidant enzyme activity, suppressed lipid peroxidation and normalized energy supply.
Evidence scope: Abstract reviewed; full text not read. Two acute models, no dose or group size in the abstract, and no chronic or human data.
Study of old rats given a kidney polypeptide complex or the peptides Cartalax, Ovagen or epitalon · Old rats
The kidney polypeptide complex and the tripeptides Cartalax and Ovagen increased diuresis 1.2 to 1.4 times; Ovagen increased sodium excretion 1.6 times; the study reported no morphological or antioxidant evidence of nephrotoxicity.
Evidence scope: Abstract reviewed; full text not read. Group sizes and doses are not in the abstract.
Molecular docking of 26 ultrashort peptides against LAT1, LAT2, PEPT1 and PEPT2, with 8,400 di- and tripeptides as comparators · Computational models, with no cells or animals
Ovagen ranked fourth of 26 at LAT1 and tenth at PEPT1; it ranked 24th at LAT2 and 25th at PEPT2, so the strongest predicted routes were LAT1 and PEPT1.
Evidence scope: Full text reviewed. Docking only; binding scores do not measure transport, and the authors did not test Ovagen uptake in cells.
History and where it stands today
Ovagen has been studied in kidney cell cultures and in rat models of acute kidney injury, and it has not entered human testing.
- 2014Two 2014 papers are central to this kidney literature: one describes Ovagen, also called T-35, in aging kidney cell cultures, and the other tests T-31 and T-35 with epitalon in experimental rhabdomyolysis [1][3].
- 2015Ovagen normalizes diuresis, creatinine excretion, glomerular filtration and sodium reabsorption in rats with cisplatin-induced acute renal failure [4].
- 2016Docking models place Ovagen at ctcc DNA sites, in a comparison of 19 short peptides [5].
- 2017Ovagen prevents oliguria, azotemia and proteinuria and preserves antioxidant enzymes in gentamicin and ischemia-reperfusion nephropathy [6].
- 2019In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen raise diuresis 1.2 to 1.4 times, and Ovagen raises sodium excretion 1.6 times, with no morphological or antioxidant evidence of nephrotoxicity [7].
- 2021A systematic review lists it as Ovagen among short peptides and attributes renal regulation, hepatoprotection and DNA binding to it [8].
- 2023Docking of 26 ultrashort peptides ranks Ovagen fourth at LAT1 and tenth at PEPT1, with weaker scores at LAT2 and PEPT2 [10].
- October 2026As of October 2026, Ovagen has no approved human drug product and no registered clinical trial. WADA's 2026 list does not name it, and S0 covers substances without government approval for human use that no later section addresses [11]; the NCAA 2026-27 list does not name it either, and its peptide-hormone class carries a catch-all [12].
How it compares with related peptides
Bronchogen is a tetrapeptide that the same 2021 review lists for lung cell regulation and DNA binding [8]. Ovagen is a tripeptide with a renal focus. Both are short peptides in the same review, but their tissue claims point to different organs.
Epitalon is a tetrapeptide that a 2014 kidney study tested alongside Ovagen in rhabdomyolysis, and the 2021 review lists it for neuro-immuno-endocrine, circadian and geroprotective effects [3][8]. Ovagen's evidence is renal, while Epitalon's spans the pineal and aging literature. The two are separate molecules with different lengths.
Cartalax is a tripeptide that the 2021 review lists for cartilage and skin fibroblast regulation and neuronal differentiation [8]. Ovagen is also a tripeptide, but its studies center on kidney tubules and renal function. The comparison shows how the same short-peptide platform is directed at different tissues.
Side effects and safety signals
The safety record for Ovagen comes entirely from cell and animal work, and the human record is empty.
- In old rats, Ovagen increased sodium excretion, with no morphological or antioxidant evidence of nephrotoxicity [7].
- In gentamicin and ischemia-reperfusion injury, Ovagen preserved antioxidant enzyme activity and suppressed lipid peroxidation, which suggests it limited oxidative stress in kidney tissue [6].
- In cisplatin nephropathy, Ovagen improved creatinine excretion and glomerular filtration; the paper reports kidney function and does not list adverse events [4].
- The animal studies measured kidney function and oxidative stress rather than clinical adverse events, and no human adverse-event or pharmacokinetic data appear in the sources reviewed [4][6].
- Long-term risk is unmeasured: none of the studies reports chronic toxicology, genotoxicity, reproductive or carcinogenicity testing [4][6][7].
- The 2021 and 2022 reviews list hepatoprotection, but none of the primary papers reviewed tested liver injury, so liver safety is not characterized [8][9].
The future: what's next for Ovagen
No trial is registered for Ovagen. A ClinicalTrials.gov search for Ovagen on October 23, 2026 returned no study, and the sources reviewed contain no human pharmacokinetic or safety data. A first-in-human study would need a characterized drug substance, an exposure assay and a toxicology package; the sources reviewed contain none of these.
The acute kidney injury models point to the clearest near-term experiments. The 2015 and 2017 papers report benefit across several kidney pathologies, and the 2019 paper proposes Ovagen as a nephroprotective agent in kidney aging [4][6][7]. A repeat-dose study in an aged animal model with measured kidney exposure would test whether the effect persists.
The mechanism needs experimental work. The DNA site differs between the 2014 and 2016 models [2][5], and the 2023 transport scores are docking predictions, not uptake measurements [10].
As of October 2026, Ovagen has no approved human drug product and no registered clinical trial; WADA's S0 class covers unapproved substances and the NCAA peptide-hormone class covers related substances [11][12].
- Which DNA sequence Ovagen binds in living kidney cells, given that two modeling papers assign different preferred sites [2][5].
- Whether the kidney protection seen in acute rat injury translates to humans [4][6].
- How much intact tripeptide reaches kidney tissue after administration, since transport is modeled rather than measured [10].
- Whether the hepatoprotection listed in the 2021 review is a real, reproducible effect [8].
- Whether repeated exposure raises immunogenicity or organ toxicity, a question the cited studies do not test [4][6].